Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more.

    Wherever life takes you

    Excipients for Drug Formulation Orally Disintegrating Tablets (ODT)


    Orally Disintegrating Tablets - enhancing ease of use and patient compliance

    Orally disintegrating tablets (ODT), are an innovative solid oral dosage form that is becoming more and more important in the pharmaceutical market, both for prescription and over-the-counter medications. In contrast to classical tablets, ODTs are specifically designed to disintegrate directly in the patient's mouth. The disintegrated tablet can then be swallowed easily without any resistance. BASF offers a comprehensive set of excipients that help you to easily formulate your active ingredient in an effective ODT.

    Tablets that disintegrate quickly in the mouth offer several distinct advantages. They are particularily helpful for pediatric and geriatric patients who have difficulty in swallowing, as well as for patients on the move or where safe drinking water is not readily available. Swallowing difficulty is a frequent complication associated with a number of diseases including stroke, Parkinson's disease and other age-related conditions. Since there is no need to swallow bulky tablets anymore, they can significantly increase patient compliance and thus can be used for higher drug concentration.

    BASF's innovative range of excipients is revolutionizing the ease of taking medication while increasing compliance among at-risk groups. Our cutting-edge products help you to easily formulate your active ingredient in an effective ODT.

    • Ludiflash® – a co-processed excipient formulation designed to achieve reliable quick disintegration with an outstanding, creamy mouthfeel of your ODT.
    • Kollidon® CL and Kollidon® CL-SF – BASF's widely known Kollidon® CL tablet disintegrant series offers two grades that are specially suitable to disintegrate your ODT with the necessary speed and excellent mouth feel.
    • Kollicoat® Smartseal 30D – BASF's latest excipient innovation, Kollicoat® Smartseal 30D is an unique solution to an unsolved ODT problem. When it comes to pellets and particle coating, other products in the market are too tacky to be applied without individual items sticking together.

    With our commitment to helping develop new medication while increasing the ease-of-use of existing formulations, BASF is playing a vital role in improving the effectiveness of healthcare worldwide.

    Orally disintegrating tablets offer significant advantages in order to overcome certain weaknesses of classical solid oral dosage forms:
    Patient compliance is increased due to ODT superior easy way of administration
    Increased medication compliance among very young and elderly due to
    Suitable for both prescription and over-the-counter drugs
    ODTs are an on-the-go dosage form, which can be taken without water

    Webinar

    BASF pharma solutions for orally disintegrating tablets

    ODTs are becoming increasingly popular for various reasons. For the consumer or patient, they offer a much more convenient administration, while healthcare companies can use them to differentiate their offer by creating line extensions. In this webinar you will learn about three approaches to develop an ODT – direct compression, granulation & tableting and ready-to-use - and the pros and cons they offer. We will provide guidance on how to choose the right approach for your project, and will support this with a case study as well as an in-depth look at the selection of specific formulation components.

    Article

    A recent advancement in orally disintegrating formulations

    Orally disintegrating tablets (ODT) or sublingual technologies have drawn attention in the industry as a promising approach to deliver drugs in life cycle management to a wide range of the patient population. Those technologies are also aimed at patients incapable of swallowing pills, especially in pediatric and geriatric populations. The criteria for rapid dissolution and onset of active ingredients in an ODT dosage depends on the performances of individual excipients which must qualify 3 unique criteria: (i) hydrophilic in nature, (ii) dissolves quickly with good mouth feel, and (iii) is highly compressible. Identifying such excipients and/or technologies to meet these criteria could be challenging, especially to overcome the drug’s loading and stability.